Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
December 20 2023 - 8:00AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced the launch of the Myriad
Collaborative Research Registry™ (MCRR). Formerly known as the
Precise Treatment Registry, the MCRR includes new data across
germline and tumor testing results from Myriad’s cancer products on
more than one million patients. The latest enhancements make the
MCRR one of the largest pan-cancer registries freely available for
research use and supports transparent clinical data sharing to
advance the field.
The Institutional Review Board (IRB) approved registry expands
access to Myriad’s extensive repository of linked genomic and
clinical data for researchers to discover deeper insights and
accelerate the pace of precision cancer research to better prevent,
detect, and treat disease. Built on DNAnexus, a leading enterprise
Precision Health platform, the MCRR provides a secure and
easy-to-use interface for scientific data analysis, collaboration,
and discovery.
The MCRR currently contains de-identified research data across a
broad list of cancer indications and includes genomic test data
associated with family history, ethnicity, and clinical
characteristics. This multi-omic resource integrates diverse
molecular information, encompassing germline variants, RNA-based
gene expression classifiers, homologous recombination deficiency
(HRD) assessment, tumor variants, microsatellite instability (MSI),
tumor mutation burden (TMB), and PD-L1 status, together providing a
holistic view for advanced insights. The registry will continue to
expand over time and is expected to include patient outcomes,
responses to treatment, and additional tools to further enhance the
types of research that can be performed.
“Myriad’s Collaborative Research Registry provides a powerful
interface for clinicians and researchers to begin to ask and
explore first-hand important questions related to germline and
tumor genetics through the wealth of meticulously curated data the
team at Myriad has made available in this unique platform,” said
Michael J. Hall, MD, MS, Chairman, Department of Clinical Genetics,
Fox Chase Cancer Center.
Myriad is accepting research concept forms from individuals and
institutions seeking to undertake research projects. Approved
projects accessing the MCRR may result in peer-reviewed
publications impacting patient care.
“The enormity and scope of the MCRR showcases our continued
commitment to being a partner in the overall health data ecosystem
by sharing real-world data in a secure, interactive cohort
browser,” said Dale Muzzey, chief scientific officer, Myriad
Genetics. “Building on our open data sharing efforts, the goal of
the registry is to advance our understanding of cancer by getting
this expansive data set in the hands of interested researchers,
enabling them to easily access and assess the data, run their own
queries, and test hypotheses to advance patient care.”
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor Statement This press
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
statements that the registry will continue to expand over time and
is expected to include patient outcomes, responses to treatment,
and additional tools to further enhance the types of research that
can be performed. These “forward-looking statements” are
management’s expectations of future events as of the date hereof
and are subject to known and unknown risks and uncertainties that
could cause actual results, conditions, and events to differ
materially and adversely from those anticipated. Such factors
include those risks described in the company’s filings with the
U.S. Securities and Exchange Commission, including the company’s
Annual Report on Form 10-K filed on March 1, 2023, as well as any
updates to those risk factors filed from time to time in the
company’s Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. Myriad is not under any obligation, and it expressly disclaims
any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise
except as required by law.
Media
Contact: |
Investor Contact: |
Glenn Farrell |
Matt Scalo |
(385) 318-3718 |
(801) 584-3532 |
PR@myriad.com |
IR@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Oct 2023 to Oct 2024